|
|
First Data on Aliskiren in Diabetic Nephropathy
|
| Link ID |
6316 |
| Title |
First Data on Aliskiren in Diabetic Nephropathy |
| Url |
http://www.medscape.com/viewarticle/575642?src=rss |
| Description |
The first trial of the new direct renin inhibitor, aliskiren, in patients with diabetic nephropathy shows that it reduces proteinuria when added to conventional treatment. But observers say this is merely a surrogate-end-point trial and definitive guidance on how to use this drug in such patients will come only from an ongoing large outcomes study, ALTITUDE. Heartwire |
| Category |
Articles > Cardiology |
| Keywords |
|
| Date |
Jun 6, 2008 |
| Contact Name |
|
| Email |
|
Write a Review
Add to My Favorite
Refer it to Friend
Report Broken Link
|
|
Other links at Articles > Cardiology |
| 1. |
Echo Contrast Agents "Safe"; FDA Should Reconsider Warnings
|
|
|
A new analysis has shown that the benefits of using ultrasound contrast agents outweigh the risks. Most important, withholding the use of such agents in patients who need them can be detrimental, says the lead investigator. Reporting her findings last week, she called on the FDA to reconsider the warnings it has placed on these products. Heartwire
|
| 5. |
CRT Not Always Being Used in the Right Patients
|
|
|
There is a large variation in the use of cardiac resynchronization therapy throughout the US, and this technology is not always used according to the guidelines, a new registry study shows. Heartwire
|
|
|
